Case Report

Focal nodular hyperplasia after oxaliplatin-based chemotherapy: A diagnostic challenge

Lorenzo Vassallo, MDa,*, Mirella Fasciano, MDa, Mirella Fortunato, MDb, Giulio Fraternali Orcioni, MDb, Tiziana Vavalac, MDe, Daniele Regge, MDe,∗

a Department of Radiology, S.S. Annunziata Hospital, ASLCN1, Via degli Ospedali 9, 12038 Savigniano, Cuneo, Italy
b Department of Pathology, Santa Croce e Carle Hospital, Via Michele Coppino 26, 12100, Cuneo, Italy
c Department of Oncology, S.S. Annunziata Hospital, ASLCN1, Via degli Ospedali 9, 12038 Savigniano, Cuneo, Italy
d Department of Radiology, Candidolo Cancer Institute, FPO-IRCCS, Candidolo, Turin, Italy
e University of Turin Medical School, Candidolo, Turin, Italy

ABSTRACT

Chemotherapy could induce benign liver alterations presenting as diffuse or focal lesions mimicking metastases. Oxaliplatin-induced vascular liver injury is described in literature, but the association with FNH-like lesions has been reported in a limited number of cases. We herewith describe the case of a 67-year-old male, who had laparoscopic right-sided hemicolectomy, 8 years ago, because of colonic adenocarcinoma (pT3N0M0) and subsequent adjuvant chemotherapy (capecitabine + oxaliplatin), who referred to the ultrasound service of our Radiology Unit because of abdominal pain. Five-years follow-up was negative for metastases. Ultrasound examination showed 2 small hypoechoic hepatic nodules, in segment VIII and VII, confirmed at CT, suspected for metastases. FDG-PET was negative, and blood tumor markers were within normal ranges. For further evaluation we performed gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI that showed hyperintensity of the nodules in the hepatobiliary phase with central small hypointensity due to a central scar. Considering the previous oxaliplatin-based chemotherapy the findings were compatible with FNHLike lesions and the diagnostic suspicion was confirmed at ultrasound-guided core needle biopsy. Knowledge of the possible occurrence of FNH-like lesions in oncologic setting, along with the detection of typical MRI appearance, is important for appropriate management and may avoid unnecessary biopsy or surgery and reduce patients’ anxiety.

© 2022 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

* Competing Interests: The authors declare that they have no financial or personal relationship that may have inappropriately influenced them in writing this article.
* Corresponding author.
E-mail address: lorenzovassallo1987@gmail.com (L. Vassallo).
https://doi.org/10.1016/j.radcr.2022.03.020
1930-0433/© 2022 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Introduction

The onset of new hepatic lesion in a patient with a history of cancer is highly concerning for metastasis, however benign liver alterations may occur after chemotherapy treatment [1]. These chemotherapy-induced hepatopathies comprise a wide variety of parenchymal and vascular entities, presenting as diffuse or focal lesions (ie steatosis, steatohepatitis, fibrosis, pseudocirrhosis or sinusoidal obstruction syndrome) [1,2].

In the last 2 decades the use of gadoxetic acid (Gd-EOB-DTPA) in magnetic resonance imaging (MRI) has helped to overcome false-negatives in the assessment of tumor response to chemotherapy due to liver parenchymal changes [3–6]. On the other hand, focal chemotherapy-induced alterations, which were previously considered to be mainly a pathologic diagnosis, are becoming a relatively new challenge for radiologists because new chemotherapies have increased their occurrence on imaging, and the focal features may mimic hepatic metastases [7,8].

Knowledge of the possible occurrence of chemotherapy-induced hepatotoxicity, along with the recognition of the typical MRI appearance, are essential to avoid mistakes in liver metastasis detection, and to define the most appropriate clinical management strategy [1].

In particular, the extensive use of oxaliplatin to treat patients with colorectal cancer has been reported to be associated with the development of different vascular liver injuries such as sinusoidal obstruction syndrome, and focal nodular hyperplasia (FNH) [9,10]. In a few cases, these vascular changes can be so severe as to induce liver failure, and increase morbidity after hepatectomy [7]. However, in literature the association between oxaliplatin and FNH-like lesions has been reported in only a limited number of cases (less than forty) including case reports and 2 case series of 14 and 15 cases [1,9,11–15].

We reported the case of a 67-year-old man who had laparoscopic right-sided hemicolectomy, 8 years ago, and then systemic chemotherapy with XELOX regimen (capcitabine and oxaliplatin) who developed 2 focal liver nodules which turned out to be FNH-like lesions.

Case report

A 67-year-old male patient with a history of pT3N0M0 colon carcinoma with neuroendocrine differentiation, who had laparoscopic right-sided hemicolectomy 8 years ago, and was subsequently treated with 8 courses of systemic chemotherapy with XELOX regimen (oxaliplatin 130 mg day 1 and Xeloda 1000 mg/m²/12h for 14 days, every 21 days) for 6 months, was referred to the Ultrasound Service of our Radiology Unit because of abdominal pain. Computed tomography (CT) scan performed at the end of chemotherapy, 7 years ago, showed normal aspect of the liver with no evidence of focal lesions (Fig. 1); 5-years follow-up was regular.

Ultrasound examination showed 2 small hypoechoic hepatic nodules in a background of steatosis (Fig. 2). CT confirmed the onset of 2 lesions in segment VIII and VII (maximum diameter respectively 17 mm and 13 mm) characterized by intense and homogeneous contrast enhancement in the arterial phase with persistent enhancement on venous and delayed phase (Fig. 3), suspected for metastases. Then patient underwent a fluorodeoxyglucose - positron emission tomography (FDG-PET) scan that did not reveal any uptake or signs of metastases (Fig. 4). The hepatocellular liver enzymes were at upper normal limit and blood tumor markers (carcinoembryonic antigen, alpha-fetoprotein, and CA19-9) were within normal ranges.

For further evaluation, we performed Gd-EOB-DTPA-enhanced MRI of the liver: the nodules were slightly hyperintense to liver parenchyma on T2- and nearly isointense on T1- and diffusion weighted images (Fig. 5). MRI Contrast-enhanced dynamic study was similar to the CT and in the hepatobiliary phase, at 20 minutes, lesions were hyperintense with central small hypointensity due to a central scar (Fig. 6). On the basis of previous oxaliplatin-based chemotherapy the imaging findings were compatible, with FNH-like lesions.

To confirm the diagnostic suspicion, multidisciplinary team decided to perform an ultrasound-guided core needle biopsy from the largest nodule in segment VIII of the liver, At histology the lesion showed features resembling focal nodular hyperplasia such as vague nodularity, a few incomplete fibrous bands and ductular reaction, inflammation with no or minimal sinusoidal dilatation, steatosis or hemorrhage. On the basis of Masson stain and glutamine synthetase pseudo map-like the findings were in keeping with the diagnostic suspicion of FNH-like lesion [16–18] (Fig. 7). During a 24-months follow up the patient is alive, free of tumoral recurrence, and the nodules were stable in size.
Fig. 2 – The ultrasound examination performed 6 year after completion of chemotherapy showed the onset of 2 small hypoechoic hepatic nodules in a background of hepatic steatosis.

Fig. 3 – Computed tomography confirmed the presence of 2 new hepatic nodules in segment VIII and VII slightly hyperdense on unenhanced CT (A), characterized by intense and homogeneous contrast enhancement in the arterial phase (B) with persistent enhancement on venous (C) and delayed phase (D), suspected for metastases.
Discussion

We presented the case of a patient affected by colorectal cancer who developed 2 FNH-like lesions after oxaliplatin-based chemotherapy.

FNH represent a benign condition that affects normal liver, with a prevalence in ultrasound studies ranging between 0.8% and 3.2% [19]. Histologically, FNH contains all the cell types found in normal hepatic parenchyma, but their structural organization is anomalous. The lesion includes a rearrangement of structurally normal hepatocytes and Kupffer cells with foci of bile-duct proliferation. The bile ducts within the nodule’s present signs of active, exuberant proliferation, and they are not connected to the biliary tree. The ducts themselves (especially those in the peripheral regions of the fibrous septa) are surrounded by an intense inflammatory infiltrate [20].

Occasionally, the perisepal zones display evidence of fatty degeneration, bile formation, and Mallory bodies. Specific assays for copper may reveal deposits of the metal within the nodules [20].

Its clinical course is mostly asymptomatic and, therefore, FNH is often diagnosed incidentally during routine abdominal imaging. Because of typical imaging appearance, liver biopsy is not required in most cases and, if performed, has excellent diagnostic performance [20].

FNH-like lesions can occur de novo after systemic chemotherapy and they were initially described in children or young adults treated with high-dose chemotherapy or undergoing chemotherapy before hematopoietic stem cell transplantation [21–26].

Although the exact etiology of FNH is unknown, it is thought to be initiated by local changes in liver perfusion causing a hyperplastic regenerative response of the liver parenchyma. In patients receiving oxaliplatin-based chemotherapy, such changes may be due to portal vein injuries at the level of the sinusoids, and the resulting portal hypertension plays an important role. The natural history of these lesions remains unknown, too. Few spontaneous regressions after the suspension of the chemotherapy have been reported as well as some protective effects of bevacizumab on the development of this toxicity [1,7].

The exact prevalence of the alteration is still unknown [1,10]: in literature the association between oxaliplatin and FNH-like lesions has been reported in only a limited number of patients including occasional case reports and 2 case series with respectively 14 and 15 patients [1,9,11–15].

Post oxaliplatin-based chemotherapy FNH-like lesions are usually multiple and the mean interval between the completion of treatment and the identification of new lesions was 48 months These alterations are generally smaller than classic FNH and up to 42% of them may increase in size at imaging after a mean follow-up of 29 months; importantly the interval for occurrence of hepatic metastases from colorectal cancer is much shorter. Therefore, the long interval for the lesion occurrence along with typical imaging appearance at MRI are important features to exclude metastases [1,27].

In our case, we identified 2 FNH-like lesions, with a maximum diameter respectively of 17 mm and 13 mm, 72 months after the end of chemotherapy and the nodules remained stable in size during a 24-months follow-up.
In many of the cases reported in literature, despite the typical imaging findings patients underwent biopsy or surgical resection because the lack of significant knowledge of this association, and the concern for delaying a diagnosis of metastasis [9,26].

FNH-like nodules do not have any risk of malignant transformation and, therefore, do not require any follow-up or treatment. However, because of the development of multiple de novo lesions after chemotherapy and the potential increase in size, the radiologist should know the typical imaging features of FNH-like lesions to avoid a misdiagnosis of hepatic metastases [7].

In particular, MRI with hepatobiliary contrast agents represent the imaging modality of choice for the diagnosis of FNH-like lesions. At MRI, FNH-like lesions are nearly isointense to liver parenchyma on T2-, T1- and diffusion-weighted images; after contrast medium administration they demonstrated homogeneous and strong enhancement in the arterial phase and persistent enhancement on portal venous or delayed phase in most cases; however, washout may be occasionally detected and, in these cases, the differential diagnosis with HCC is difficult. In the hepatobiliary phase, FNH-like nodules are usually hyper- or isointense to the surrounding liver parenchyma, due to equal or higher OATP1B3 expression compared with the background liver tissue, and a ring (or doughnut-like) pattern is observed in approximately 50% cases. Usually the signal intensity is homogenously iso- to hyperintense on hepatobiliary when lesions are small, while it may demonstrate a hyperintense rim, and a central hypointense area if the lesions is larger [1,7,28–30].

In healthy and oncologic patients, FNH and FNH-like lesions are likely the most common lesions showing hyperintensity on hepatobiliary phase; while in cirrhotic patients imaging evaluation should be aimed at excluding the presence of the small proportion of HCC that may show hyperintensity in hepatobiliary phase [7,31].

In our case, the neuroendocrine differentiation of the colonic adenocarcinoma could increase the challenges in differential diagnosis because also metastases from a neuroendocrine tumor typically show strong enhancement on arterial
phase however the hyperintensity in the hepatobiliary phase was highly predictive of FNH-like lesions.

In this specific clinical setting, negative FDG-PET, although important to exclude liver metastases, has some limitations considering the tendency of lower accuracy of FDG-PET after chemotherapy [32].

In conclusion, an increasing proportion of patients with colorectal cancer nowadays receive oxaliplatin-based chemotherapy with the risk for development a wide variety of parenchymal and vascular injuries, such as FNH-like lesions. Knowledge of the possible occurrence of these liver alterations in oncologic setting, along with the detection of typical MRI appearance, may reduce the risk of misdiagnosing these lesions as metastases while directing the patient toward a conservative management avoiding unnecessary biopsy or surgery. Moreover, this case confirms the value of hepatobiliary contrast agents in the evaluation of the liver in patients with cancer, not only for the detection of small metastases but also for the differentiation of metastases from benign lesions.
Patient consent

Written informed consent was obtained from the patient. The data that support the findings of this study are available from the corresponding author, (LV), upon reasonable request.

We confirm that this work is original and has not been published elsewhere nor it is currently under consideration for publication elsewhere.

REFERENCES

[1] Furlan A, Brancatelli A, Dioguardi Burgio M, Graziolli L, Lee JM, Murmura E, et al. Focal nodular hyperplasia after treatment with oxaliplatin: a multi-institutional series of cases diagnosed at MRI. AJR. 2018;210:775–9. doi:10.2214/AJR.17.18867.

[2] Han NY, Park BJ, Sung DJ, Kim MJ, Cho SB, Lee CH, et al. Chemotherapy-induced focal hepatopathy in patients with gastrointestinal malignancy: gadoxic acid-enhanced and diffusion-weighted MR imaging with clinical–pathologic correlation. Radiology. 2014;271:416–25. doi:10.1148/radiol.13131810.

[3] Shin NY, Kim MJ, Lim JS, Park MS, Chung YE, Choi JY, et al. Accuracy of gadoxic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. Eur Radiol 2012;22:864–71. doi:10.1007/s00330-011-2333-x.

[4] Kim A, Lee CH, Kim BH, Lee J, Choi JW, Park YS, et al. Gadoxic acid-enhanced 3.0T MRI for the evaluation of hepatic metastases from colorectal cancer: metastasis is not always seen as a “defect” on the hepatobiliary phase. Eur J Radiol 2012;81:3998–4004. doi:10.1016/j.ejrad.2012.03.032.

[5] Yoneda N, Matsui O, Kitaos A, Kozaka K, Kobayashi S, Sasaki M, et al. Benign hepatocellular nodules: hepatobiliary phase of gadoxic acid-enhanced MR imaging based on molecular background. Radiographics. 2016;36:2010–27. doi:10.1148/rg.2016160037.

[6] Unal E, Karacosmanoglou AD, Ozmen MN, Akata D, Karcaaltincaba M. Hepatobiliary phase MR liver imaging findings after Oxaliplatin-based chemotherapy in cancer patients. Abdom Radiol 2018;43(9):2321–8. doi:10.1007/s00261-018-1482-7.

[7] Vennuccio F, Gagliano DS, Cannella R, Ba-Ssalamah A, Tang A, Brancatelli G. Spectrum of liver lesions hyperintense on hepatobiliary phase: an approach by clinical setting. Insights Imaging 2021;12(8). doi:10.1186/s13244-020-00928-w.

[8] Morana G, Graziolli L, Kirchin MA, Bondioni MF, Faccioli N, Guarise A, et al. Solid hepaticovascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration. Invest Radiol 2011;46:225–39. doi:10.1097/RLI.0b013e3181e3fe53a.

[9] Brunet A, Beaufreire A, Cauchy F, Paradis V. Focal nodular hyperplasia after systemic chemotherapy: pathological features of a series of 15 cases. Liver Cancer Int 2021;00:1–6. doi:10.1002/lci2.32.

[10] Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010;56:430–9. doi:10.1111/j.1365-2559.2010.03511.x.

[11] Donadon M, Di Tommaso L, Roncalli M, Torzilli G. Multiple focal nodular hyperplasias induced by oxaliplatin-based chemotherapy. World J Hepatol 2013;6(5):340–4. doi:10.4254/wjh.v6.i5.340.

[12] Tenorio LP, Miranda MFO, Andrade MQ, Araujo MN. Hepatic changes after treatment with oxaliplatin. Radiol Bras 2019;52(5):342–8. doi:10.1590/0039-3984.2017.0173.

[13] De Wert LA, Huisman SA, de Gooyer DJ, van Riel JMGH, Gobardhan PD, Rijken AM, et al. Appearance of focal nodular hyperplasia after chemotherapy in two patients during follow-up of colon carcinoma. Case Rep Surg 2021;2021:6676109. doi:10.1155/2021/6676109.

[14] Shilomai A, Tobar A, Benjamins M. Multiple liver lesions after oxaliplatin-based chemotherapy for colorectal cancer. Gastroenterology 2015;149:e1–3. doi:10.1053/j.gastro.2015.02.017.

[15] Jain C, Syed A, Gupta N, Kamboj M, Rao A, Singh S. Oxaliplatin-induced multiple focal nodular hyperplasia masquerading as colorectal liver metastasis—case report and review of literature. J Gastrointest Cancer 2020;51:628–30. doi:10.1007/s12029-019-00307-9.

[16] Bioulac-Sage P, Cubel G, Taoji S, Leteurtre E, Paradis V, Sturm N, et al. Immunohistochemical markers on needle biopsies are helpful for the diagnosis of focal nodular hyperplasia and hepatocellular adenoma subtypes. Am J Surg Pathol 2012;36:1691–9.

[17] Bioulac-Sage P, Laumonier H, Rullier A, Cubel G, Laurent C, Zucman-Rossi J, et al. Over-expression of glutamine synthetase in fetal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver Int 2009;29:459–65. doi:10.1111/j.1478-3231.2008.01731.x.

[18] Reboissaux S, Couchy G, Libbrecht L, Balbaud C, Imbeaud S, Auffray C, et al. The beta-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules. J Hepatol 2008;49:61–71. doi:10.1016/j.jhep.2008.03.013.

[19] Kaltenbach TE, Engler P, Kratzew W, Oezteuerk S, Seufferlein T, Haenle MM, et al. Prevalence of benign focal liver lesions: ultrasound investigation of 45319 hospital patients. Abdom Radiol 2016;41:25–32. doi:10.1007/s00261-015-0605-7.

[20] Nguyen BN, Flejou JF, Terris B, Belghiti J, Degott C. Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol 1999;23(12):1441–54. doi:10.1097/00000478-199912000-00001.

[21] Bouyn CI, Leclere J, Raimondo G, Le Pointe HD, Couanet D, Valteau-Couanet D, et al. Hepatic focal nodular hyperplasia in children previously treated for a solid tumor. Incidence, risk factors and outcome. Cancer 2003;97:3107–13. doi:10.1002/cncr.11452.

[22] Smith EA, Salisbury S, Martin R, Towbin AJ. Incidence and etiology of new liver lesions in pediatric patients previously treated for malignancy. Am J Roentgenol 2012;199:186–91. doi:10.2214/AJR.11.7690.

[23] Benz-Bohm G, Hero B, Gossmann A, Simon T, Korber F, Berthold F, et al. Focal nodular hyperplasia of the liver in longterm survivors of neuroblastoma: how much diagnostic imaging is necessary? Eur J Radiol 2010;74:e1–5. doi:10.1016/j.ejrad.2009.03.011.

[24] Lee MH, Yoo SY, Kim JH, Eo H, Jeon TY, Kim SH, et al. Hypervascular hepatic nodules in childhood cancer survivors: clinical and imaging features. Clin Imaging 2012;36:301–6. doi:10.1016/j.clinimag.2011.11.004.

[25] Pillon M, Carucci NS, Mainardi C, Carrao R, Zuliani M, Chemello L, et al. Focal nodular hyperplasia of the liver: an emerging complication of hematopoietic SCT in children. Bone Marrow Transplant 2015;50:414–19. doi:10.1038/bmt.2014.276.
[26] De Pasquale MD, Monti L, D’Andrea ML, De Ioris MA, Castellano A. Focal nodular hyperplasia and hepatic regenerating nodules in pediatric oncology patients: how much invasive approach is necessary? Ann Hepatol 2013;12:308–14.

[27] Walter CJ, Al-Allak A, Borley N, Goodman A, Wheeler JM. Fifth-year surveillance computed tomography scanning after curative resection for colorectal cancer. Surgeon 2013;11:25–9. doi:10.1016/j.surge.2012.01.005.

[28] Suh CH, Kim KW, Kim GY, Shin YM, Kim PN, Park SH. The diagnostic value of Gd-EOB-DTPA MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis. Eur Radiol 2015;25:950–60. doi:10.1007/s00330-014-3499-9.

[29] McInnes MD, Hibbert RM, Inacio JR, Schieda N. Focal nodular hyperplasia and hepatocellular adenoma: accuracy of gadoxetic acid-enhancement MR imaging – a systematic review. Radiology 2015;277:413. doi:10.1148/radiol.2015142986.

[30] Albano D, Benenati M, Bruno A, Bruno F, Calandri M, Caruso D, et al. Imaging side effects and complications of chemotherapy and radiation therapy: a pictorial review from head to toe. Insights Imaging 2021;12(1):76. doi:10.1186/s13244-021-01017-2.

[31] Kim JY, Kim MJ, Kim KA, Jeong HT, Park YN. Hyperintense HCC on hepatobiliary phase images of gadoxetic acid-enhanced MRI: correlation with clinical and pathological features. Eur J Radiol 2012;81:3877–82. doi:10.1016/j.ejrad.2012.07.021.

[32] Lubezky N, Metser U, Geva R, Nakache R, Shmueli E, Klausner JM, et al. The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg 2007;11:472–8. doi:10.1007/s11605-006-0032-8.